AIDS Therapies (GEM 92)

Clinical Trials of Antisense Compound for AIDS Treatment Initiated

Published in AIDS Weekly, September 29th, 1997

Hybridon, Inc., Cambridge, Massachusetts, announced that it has initiated a clinical trial of the oral administration of GEM 92.

GEM 92 is a second generation, mixed backbone antisense compound for the treatment of HIV and AIDS. GEM 92 targets the gag site in the HIV genome. Hybridon believes that this is the first study in humans to investigate the potential for oral delivery of an antisense oligonucleotide.

The company has planned to conduct the clinical trial in the United Kingdom and expects the trial to involve approximately 13 normal volunteers. The company intends to administer to each volunteer a single dose at one of three dose...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry